Hepatocellular Carcinoma Treatment Advances

Expert panelists center discussion on patient cases to highlight optimal management strategies in patients with hepatocellular carcinoma.

EP. 1: Case 1: A 60-Year-Old With Unresectable Hepatocellular Carcinoma

June 24th 2022

Sharing the first patient case of unresectable hepatocellular carcinoma, experts consider optimal screening and diagnosis practices in this setting.

EP. 2: Case 1: Role of TARE in Unresectable Hepatocellular Carcinoma

June 24th 2022

Expert perspectives on the role of transarterial radioembolization in unresectable hepatocellular carcinoma following FDA approval.

EP. 3: Case 1: Systemic Therapy in Combination With or Following TACE/TARE

July 1st 2022

A brief discussion on the role of systemic therapies in combination with or following TACE/TARE in unresectable hepatocellular carcinoma.

EP. 4: Case 2: A 75-Year-Old With Metastatic HCC

July 1st 2022

Shifting to a second patient case of metastatic hepatocellular carcinoma, experts consider best diagnostic practices and the initiation of therapy.

EP. 5: Case 2: Role of Biopsy and Imaging in Metastatic HCC

July 8th 2022

Panelists debate the role of imaging in conjunction with or in place of biopsy in the setting of metastatic hepatocellular carcinoma.

EP. 6: Case 2: Selecting Frontline Therapy for Metastatic HCC

July 8th 2022

Focused discussion on the frontline treatment options available for patients diagnosed with metastatic hepatocellular carcinoma.

EP. 7: Case 2: Data Supporting Frontline TKI Therapy in Metastatic HCC

July 15th 2022

Shared insight on clinical trial data in metastatic hepatocellular carcinoma supporting frontline use of sorafenib and lenvatinib, respectively.

EP. 8: Case 2: PFS Subgroup Data From the REFLECT Trial in Metastatic HCC

July 15th 2022

Comprehensive discussion on the PFS subgroup data from REFLECT, which compared frontline lenvatinib and sorafenib therapy in metastatic HCC.

EP. 9: Case 2: Adverse Event Management and Dosing of Frontline TKIs

July 22nd 2022

Panelists consider the adverse event profile of frontline TKI therapy in patients with metastatic HCC and review options for dosing and dose reduction.

EP. 10: Case 2: Treating Child-Pugh B Metastatic Hepatocellular Carcinoma

July 22nd 2022

A brief review of treatment options for patients with Child-Pugh B grade metastatic hepatocellular carcinoma.